Abstract library

9 results for "Bernard".
#126 Assessment of the proliferation marker Ki-67 by endoscopic ultrasound guided-Fine Needle Aspiration (EUS-FNA) in pancreatic endocrine tumors: A comparative analysis with histology of the surgical specimen
Introduction: Assessment of the proliferative index by Ki-67 immuno-labelling is an important prognostic parameter for the biologic behavior of digestive neuroendocrine tumors, usually established on the histological specimen obtained after surgery or macro-biopsy. However, small pancreatic endocrine tumors (PET) are more and more often recognized by CT/MRI and diagnosed by EUS. The value of Ki-67 labelling index (Ki-67-LI) on fine needle aspiration (FNA) is not well-established in this setting, although regularly assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Miss Valérie Bernard
#544 Second Primary Tumor in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): Data From a Retrospective Observational Unicentric Study
Introduction: It is known that GEPNETs are associated with a high incidence of second primary tumors, especially in the context of inherited syndromes and synchronous injuries to the intestine.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#1309 Dual 18F-Fluorodeoxyglucose/68Gallium DOTATATE (FDG/DOTA) PET Predicts Overall Survival in Neuroendocrine Tumours (NET)
Introduction: 68Ga-DOTATATE (DOTA) and FDG PET have been utilised in NETs to aid diagnosis, prognostication and guide management. FDG PET avidity is associated with poor prognosis, but the prognostic significance of dual FDG/DOTA grading has not been explored.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr David Chan
Authors: Chan D, Bailey D, Schembri G, Bernard E, ...
Keywords: PET, prognosis
#1423 Multidisciplinary Management and Patient Flow in Neuroendocrine Tumors (NET): Consensus of a Tertiary Hospital
Introduction: Currently, there has been an improvement in diagnostic procedures and treatments of NET. Therefore, an effective teamwork is needed to choose the best approach for patients.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#1787 Towards Personalizing PRRT with [177Lu]-Dotatate to Minimise Renal Toxicity in Neuroendocrine Tumour Patients
Introduction: The kidney is a dose-limiting organ in [177Lu]-Dotatate PRRT (Lutate) and thus renal function is an important prescribing consideration for NET patients. The effect of baseline renal function on kidney absorbed dose is unclear.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Enid Eslick
#1889 FNA Under Percutaneous Ultrasound or Endoscopic Ultrasound for Pre-Operative Diagnosis and Grading Determination in PanNET. Are They Reliable to Define a Tailored Therapy?
Introduction: Fine-needle aspiration cytology (FNA)under percutaneous ultrasound guided (pUS)or endoscopic ultrasound(EUS)control is a minimally invasive technique allowing diagnosis and grading determination in pancreatic neuroendocrine tumors (PanNET).Obtaining a correct cytological diagnosis is crucial for a tailored therapy
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: MD Roberta Rota
Keywords: FNA, Ki67
#1943 Neuroendocrine Tumors Committee of Reference Hospital: Evaluation of Health Care and Research Indicators
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers which optimize results improving care and survival.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD-PhD Paula Jimenez Fonseca
#2293 Genomic and Transcriptomic Characterization of Aggressive Well Differentiated Pancreatic Neuroendocrine Tumors (WD PanNET)
Introduction: While the genomic and transcriptomic landscape of low proliferating PanNET have been well studied, pathways driving aggressive WD PanNET are still unclear.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Jerome Cros
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.